Methods and materials for identifying and treating monoclonal and oligoclonal gammopathies
AssigneeMayo Foundation for Medical Education and Research
InventorsDavid L. Murray, Anand Padmanabhan
Life of this patent
Estimating the term…
Abstract
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having a monoclonal or oligoclonal gammopathy of thrombotic/thrombocytopenia significance (MGTS). For example, the presence of a population of monoclonal antibodies having binding specificity for a platelet factor 4 (PF4) polypeptide in a sample obtained from a mammal (e.g., a human) can be used to identify the mammal as having MGTS. In some cases, materials and methods for treating a mammal (e.g., a human) identified as having MGTS are provided.
Claims32
A method for detecting a population of monoclonal antibodies specific for a platelet factor 4 (PF4) polypeptide in a sample obtained from a mammal, said method comprising:
- immunopurifying antibodies specific for said PF4 polypeptide from the sample;
- subjecting the immunopurified immunoglobulins to a mass spectrometry technique to obtain a mass spectrum of the sample;
- and
- identifying the presence of said population of monoclonal antibodies specific for said PF4 polypeptide based on a peak in the spectrum corresponding to the monoclonal antibodies specific for said PF4 polypeptide.
A method for detecting a population of oligoclonal antibodies specific for a platelet factor 4 (PF4) polypeptide in a sample obtained from a mammal, said method comprising:
- immunopurifying antibodies specific for said PF4 polypeptide from the sample;
- subjecting the immunopurified immunoglobulins to a mass spectrometry technique to obtain a mass spectrum of the sample;
- and
- identifying the presence of said population of oligoclonal antibodies specific for said PF4 polypeptide based on a peak in the spectrum corresponding to the monoclonal antibodies specific for said PF4 polypeptide.
3-5. (canceled)
8-10. (canceled)
A method for assessing a mammal having a thrombotic and/or thrombocytopenia condition, wherein said method comprises:
- (a) detecting, in a sample from said mammal, a presence or absence of a population of monoclonal antibodies having binding specificity for a PF4 polypeptide;
- (b) classifying said mammal as having monoclonal gammopathy of thrombotic/thrombocytopenia significance (MGTS) if said presence of said population is detected;
- and
- (c) classifying said mammal as not having MGTS if said absence of said population level is detected.
(canceled)
14-16. (canceled)
(canceled)
21-23. (canceled)
A method for treating a mammal having a thrombotic and/or thrombocytopenia condition, wherein said method comprises:
- (a) detecting, in a sample obtained from said mammal, a population of monoclonal antibodies having binding specificity for a PF4 polypeptide;
- and
- (b) administering a therapy effective to treat a monoclonal gammopathy to said mammal.
(canceled)
27-29. (canceled)
(canceled)
34-36. (canceled)
A method for treating a mammal having a thrombotic and/or thrombocytopenia condition, wherein said method comprises:
- (a) detecting, in a sample obtained from said mammal, an absence of a population of monoclonal antibodies having binding specificity for a PF4 polypeptide;
- and
- (b) administering a therapy effective to treat thrombosis to said mammal.
(canceled)
40-42. (canceled)
(canceled)
Dependencies are inferred from the claim text.